Hi come on_老虎社区_美港股上老虎

SDQwerty
2021-03-18

Hi come on

Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote>

(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business U

Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":327181015,"tweetId":"327181015","gmtCreate":1616069930337,"gmtModify":1634527403620,"author":{"id":3561701296039483,"idStr":"3561701296039483","authorId":3561701296039483,"authorIdStr":"3561701296039483","name":"SDQwerty","avatar":"https://static.tigerbbs.com/91dd9a7c9982bff6f674211becf77da3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Hi come on</body></html>","htmlText":"<html><head></head><body>Hi come on</body></html>","text":"Hi come on","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/327181015","repostId":1141211447,"repostType":4,"repost":{"id":"1141211447","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1616067847,"share":"https://www.laohu8.com/m/news/1141211447?lang=zh_CN&edition=full","pubTime":"2021-03-18 19:44","market":"us","language":"en","title":"Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141211447","media":"Tiger Newspress","summary":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business U","content":"(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.<blockquote>（3月18日）传奇生物公布2020年第四季度及全年财务业绩及业务更新。</blockquote> <ul> <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li> <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li> </ul> <img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"><blockquote><ul><li>传奇生物：第四季度GAAP每股收益为-0.22美元超过预期为0.08美元。</li><li>收入为4078万美元（同比增长109.7%）超过预期2878万美元。</li></ul></blockquote> Financial Results for the Quarter and Year Ended December 31, 2020<blockquote>截至2020年12月31日的季度和年度财务业绩</blockquote> Cash and Cash Equivalents and time deposits:<blockquote>现金及现金等价物及定期存款：</blockquote> As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.<blockquote>截至2020年12月31日，传奇生物拥有约4.557亿美元的现金及现金等价物以及约5000万美元的定期存款。</blockquote> Revenue<blockquote>收入</blockquote> Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.<blockquote>截至2020年12月31日的三个月收入为4080万美元，而截至2019年12月31日的三个月为1950万美元。增加2130万美元主要是由于根据传奇生物与杨森的协议实现的更高金额的额外里程碑付款的收入确认以及相关的受限可变对价被解除。截至2020年12月31日止年度的收入为7570万美元，而截至2019年12月31日止年度为5730万美元。同样，截至2020年12月31日的年度增加了1840万美元，主要是由于实现了更高金额的额外里程碑而确认的收入。传奇生物迄今尚未从产品销售中产生任何收入。</blockquote> Research and Development Expenses<blockquote>研发费用</blockquote> Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.<blockquote>截至2020年12月31日的三个月的研发费用为6690万美元，而截至2019年12月31日的三个月为6610万美元。80万美元的增加主要是由于员工福利费用和研发费用的增加，但被合作研发费用的减少所抵消。截至2020年12月31日止年度的研发费用为2.322亿美元，与截至2019年12月31日止年度的1.619亿美元相比，增加了7030万美元。同比增长主要是由于截至2020年12月31日止年度临床试验数量增加、参加这些试验的患者数量增加以及研发候选产品数量增加。</blockquote> Loss for the Period<blockquote>期内亏损</blockquote> For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.<blockquote>截至2020年12月31日的三个月，净亏损为5780万美元，或每股0.22美元，而截至2019年12月31日的三个月净亏损为6390万美元，或每股0.32美元。截至2020年12月31日的年度净亏损为3.035亿美元，或每股1.28美元，而截至2019年12月31日的年度净亏损为1.33亿美元，或每股0.66美元。</blockquote> Key Upcoming Milestones<blockquote>即将到来的关键里程碑</blockquote> <ul> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li> <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li> <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li> <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li> <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li> </ul> As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.<blockquote><ul><li>传奇生物的合作者杨森预计将于2021年上半年向EMA提交cilta-cel治疗成人RRMM的MAA。</li><li>传奇生物打算使用CARTIFAN-1研究的数据来支持向中国药品审评中心（CDE）提交的监管文件，寻求批准cilta-cel用于治疗成人RRMM。传奇生物预计将于2021年下半年提交申请。</li><li>传奇生物的合作者杨森预计将于2021年下半年向日本厚生劳动省（JMHLW）提交新药申请（NDA），寻求批准cilta-cel用于治疗成人RRMM。</li><li>传奇生物预计将于2021年在美国启动LB1901在RR TCL的1期临床试验。</li><li>传奇生物与杨森合作，打算在2021年的主要医学会议上展示CARTITUDE-1的最新数据和CARTITUDE-2研究的数据。</li><li>传奇生物预计将于2021年支持研究人员发布LEGEND-2研究的临床数据更新。</li></ul>随著全球COVID-19疫情持续发展，传奇生物持续监控其营运情况，并已采取重大措施保护供应链、营运、僱员及临床试验的执行。鉴于全球形势的动态，传奇生物指出，某些临床试验时间表可能会受到影响。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-03-18 19:44\n</div>\n</a>\n</h4>\n</header>\n<article>\n(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.<blockquote>（3月18日）传奇生物公布2020年第四季度及全年财务业绩及业务更新。</blockquote> <ul> <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li> <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li> </ul> <img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"><blockquote><ul><li>传奇生物：第四季度GAAP每股收益为-0.22美元超过预期为0.08美元。</li><li>收入为4078万美元（同比增长109.7%）超过预期2878万美元。</li></ul></blockquote> Financial Results for the Quarter and Year Ended December 31, 2020<blockquote>截至2020年12月31日的季度和年度财务业绩</blockquote> Cash and Cash Equivalents and time deposits:<blockquote>现金及现金等价物及定期存款：</blockquote> As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.<blockquote>截至2020年12月31日，传奇生物拥有约4.557亿美元的现金及现金等价物以及约5000万美元的定期存款。</blockquote> Revenue<blockquote>收入</blockquote> Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.<blockquote>截至2020年12月31日的三个月收入为4080万美元，而截至2019年12月31日的三个月为1950万美元。增加2130万美元主要是由于根据传奇生物与杨森的协议实现的更高金额的额外里程碑付款的收入确认以及相关的受限可变对价被解除。截至2020年12月31日止年度的收入为7570万美元，而截至2019年12月31日止年度为5730万美元。同样，截至2020年12月31日的年度增加了1840万美元，主要是由于实现了更高金额的额外里程碑而确认的收入。传奇生物迄今尚未从产品销售中产生任何收入。</blockquote> Research and Development Expenses<blockquote>研发费用</blockquote> Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.<blockquote>截至2020年12月31日的三个月的研发费用为6690万美元，而截至2019年12月31日的三个月为6610万美元。80万美元的增加主要是由于员工福利费用和研发费用的增加，但被合作研发费用的减少所抵消。截至2020年12月31日止年度的研发费用为2.322亿美元，与截至2019年12月31日止年度的1.619亿美元相比，增加了7030万美元。同比增长主要是由于截至2020年12月31日止年度临床试验数量增加、参加这些试验的患者数量增加以及研发候选产品数量增加。</blockquote> Loss for the Period<blockquote>期内亏损</blockquote> For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.<blockquote>截至2020年12月31日的三个月，净亏损为5780万美元，或每股0.22美元，而截至2019年12月31日的三个月净亏损为6390万美元，或每股0.32美元。截至2020年12月31日的年度净亏损为3.035亿美元，或每股1.28美元，而截至2019年12月31日的年度净亏损为1.33亿美元，或每股0.66美元。</blockquote> Key Upcoming Milestones<blockquote>即将到来的关键里程碑</blockquote> <ul> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li> <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li> <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li> <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li> <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li> </ul> As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.<blockquote><ul><li>传奇生物的合作者杨森预计将于2021年上半年向EMA提交cilta-cel治疗成人RRMM的MAA。</li><li>传奇生物打算使用CARTIFAN-1研究的数据来支持向中国药品审评中心（CDE）提交的监管文件，寻求批准cilta-cel用于治疗成人RRMM。传奇生物预计将于2021年下半年提交申请。</li><li>传奇生物的合作者杨森预计将于2021年下半年向日本厚生劳动省（JMHLW）提交新药申请（NDA），寻求批准cilta-cel用于治疗成人RRMM。</li><li>传奇生物预计将于2021年在美国启动LB1901在RR TCL的1期临床试验。</li><li>传奇生物与杨森合作，打算在2021年的主要医学会议上展示CARTITUDE-1的最新数据和CARTITUDE-2研究的数据。</li><li>传奇生物预计将于2021年支持研究人员发布LEGEND-2研究的临床数据更新。</li></ul>随著全球COVID-19疫情持续发展，传奇生物持续监控其营运情况，并已采取重大措施保护供应链、营运、僱员及临床试验的执行。鉴于全球形势的动态，传奇生物指出，某些临床试验时间表可能会受到影响。</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEGN":"传奇生物"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141211447","content_text":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.\n\nLegend Biotech : Q4 GAAP EPS of -$0.22beats by $0.08.\nRevenue of $40.78M (+109.7% Y/Y)beats by $28.78M.\n\n\nFinancial Results for the Quarter and Year Ended December 31, 2020\nCash and Cash Equivalents and time deposits:\nAs of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.\nRevenue\nRevenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.\nResearch and Development Expenses\nResearch and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.\nLoss for the Period\nFor the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.\nKey Upcoming Milestones\n\nLegend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.\nLegend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.\nLegend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.\nLegend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.\nLegend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.\nLegend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.\n\nAs the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.","news_type":1,"symbols_score_info":{"LEGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1283,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}